Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Honegger

Showing results (41-50 of 48) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 48 results.
Cancer|September 1, 1981
Thrombin inhibition by malignant and normal cells: a cell-bound antithrombin effectJ L Tullis, H Honegger, O Fleischaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomasR A Stahel, L M Jost, H Honegger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignanciesR A Stahel, L M Jost, T Cerny, et al.
Blood|August 1, 1983
Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemiaJ Gmür, A von Felten, B Osterwalder, et al.
British Journal of Haematology|April 7, 1999
A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remissionR A Stahel, L M Jost, T Kroner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2005
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicityM M Borner, J Bernhard, D Dietrich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2000
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO)A D Roth, R Maibach, G Martinelli, et al.
British Journal of Cancer|April 20, 2006
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II studyD C Betticher, S-F Hsu Schmitz, M Tötsch, et al.
Pageof 5

Showing results (41-50 of 48) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 48 results.
Cancer|September 1, 1981
Thrombin inhibition by malignant and normal cells: a cell-bound antithrombin effectJ L Tullis, H Honegger, O Fleischaker, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 1, 1997
Randomized trial showing equivalent efficacy of filgrastim 5 micrograms/kg/d and 10 micrograms/kg/d following high-dose chemotherapy and autologous bone marrow transplantation in high-risk lymphomasR A Stahel, L M Jost, H Honegger, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 1, 1994
Randomized study of recombinant human granulocyte colony-stimulating factor after high-dose chemotherapy and autologous bone marrow transplantation for high-risk lymphoid malignanciesR A Stahel, L M Jost, T Cerny, et al.
Blood|August 1, 1983
Delayed alloimmunization using random single donor platelet transfusions: a prospective study in thrombocytopenic patients with acute leukemiaJ Gmür, A von Felten, B Osterwalder, et al.
British Journal of Haematology|April 7, 1999
A prospective study of risk-adapted therapy for large cell non-Hodgkin's lymphoma with VACOP-B followed by high-dose CBV and autologous progenitor cell transplantation for high-risk patients in remissionR A Stahel, L M Jost, T Kroner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 26, 2005
A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicityM M Borner, J Bernhard, D Dietrich, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 16, 2000
Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO)A D Roth, R Maibach, G Martinelli, et al.
British Journal of Cancer|April 20, 2006
Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a phase II studyD C Betticher, S-F Hsu Schmitz, M Tötsch, et al.
Pageof 5